Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02693535
Title TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors American Society of Clinical Oncology
Indications

Advanced Solid Tumor

multiple myeloma

B-cell lymphoma

Therapies

Cobimetinib + Vemurafenib

Atezolizumab + Talazoparib

Regorafenib

Larotrectinib

Trastuzumab + Tucatinib

Ipilimumab + Nivolumab

Palbociclib

Afatinib

Entrectinib

Talazoparib

Pembrolizumab

Temsirolimus

Pertuzumab + Trastuzumab

Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf

Crizotinib

Abemaciclib

Sunitinib

Olaparib

Age Groups: child | senior | adult
Covered Countries USA